Targeting platelets for the treatment of cancer
The majority of cancer-associated mortality results from the ability of tumour cells to metastasise leading to multifunctional organ failure and death. Disseminated tumour cells in the blood circulation are faced with major challenges such as rheological shear stresses and cell-mediated cytotoxicity...
| Main Authors: | , , , |
|---|---|
| Format: | Journal Article |
| Published: |
MDPI AG
2017
|
| Online Access: | http://hdl.handle.net/20.500.11937/56077 |
| _version_ | 1848759781241651200 |
|---|---|
| author | Elaskalani, Omar Berndt, Michael Falasca, Marco Metharom, Pat |
| author_facet | Elaskalani, Omar Berndt, Michael Falasca, Marco Metharom, Pat |
| author_sort | Elaskalani, Omar |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | The majority of cancer-associated mortality results from the ability of tumour cells to metastasise leading to multifunctional organ failure and death. Disseminated tumour cells in the blood circulation are faced with major challenges such as rheological shear stresses and cell-mediated cytotoxicity mediated by natural killer cells. Nevertheless, circulating tumour cells with metastatic ability appear equipped to exploit host cells to aid their survival. Despite the long interest in targeting tumour-associated host cells such as platelets for cancer treatment, the clinical benefit of this strategy is still under question. In this review, we provide a summary of the latest mechanistic and clinical evidence to evaluate the validity of targeting platelets in cancer. |
| first_indexed | 2025-11-14T10:05:20Z |
| format | Journal Article |
| id | curtin-20.500.11937-56077 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T10:05:20Z |
| publishDate | 2017 |
| publisher | MDPI AG |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-560772017-10-19T03:53:53Z Targeting platelets for the treatment of cancer Elaskalani, Omar Berndt, Michael Falasca, Marco Metharom, Pat The majority of cancer-associated mortality results from the ability of tumour cells to metastasise leading to multifunctional organ failure and death. Disseminated tumour cells in the blood circulation are faced with major challenges such as rheological shear stresses and cell-mediated cytotoxicity mediated by natural killer cells. Nevertheless, circulating tumour cells with metastatic ability appear equipped to exploit host cells to aid their survival. Despite the long interest in targeting tumour-associated host cells such as platelets for cancer treatment, the clinical benefit of this strategy is still under question. In this review, we provide a summary of the latest mechanistic and clinical evidence to evaluate the validity of targeting platelets in cancer. 2017 Journal Article http://hdl.handle.net/20.500.11937/56077 10.3390/cancers9070094 MDPI AG fulltext |
| spellingShingle | Elaskalani, Omar Berndt, Michael Falasca, Marco Metharom, Pat Targeting platelets for the treatment of cancer |
| title | Targeting platelets for the treatment of cancer |
| title_full | Targeting platelets for the treatment of cancer |
| title_fullStr | Targeting platelets for the treatment of cancer |
| title_full_unstemmed | Targeting platelets for the treatment of cancer |
| title_short | Targeting platelets for the treatment of cancer |
| title_sort | targeting platelets for the treatment of cancer |
| url | http://hdl.handle.net/20.500.11937/56077 |